Journal
DIABETES CARE
Volume 33, Issue 7, Pages 1674-1685Publisher
AMER DIABETES ASSOC
DOI: 10.2337/dc10-0666
Keywords
-
Categories
Funding
- Amylin Pharmaceuticals, Inc.
- Lilly USA
- Merck Company, Inc.
- Novo Nordisk A/S
- Sanofi-aventis Groupe
- Amylin
- Bayer Diabetes Care
- Eli Lilly
- Mannkind
- Medtronic
- National Institutes of Health (NIH)
- Novo Nordisk
- ResMed
- Life Scan
- American Diabetes Association
Ask authors/readers for more resources
Epidemiologic evidence suggests that cancer incidence is associated with diabetes as well as certain diabetes risk factors and diabetes treatments. This consensus statement of experts assembled jointly by the American Diabetes Association and the American Cancer Society reviews the state of science concerning 1) the association between diabetes and cancer incidence or prognosis, 2) risk factors common to both diabetes and cancer, 3) possible biologic links between diabetes and cancer risk, and 4) whether diabetes treatments influence risk of cancer or cancer prognosis. In addition, key unanswered questions for future research are posed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available